NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/25/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization146.47 mln
Float36.97 mln
Earnings Date11/18/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
8.56
Transformational upside
Relative Strength
26
/ 100
Underperforming
Debt / Equity
0.01
Debt-free
ROE
-70.75
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Equillium is a US-based biotechnology company focused on developing treatments for serious immune system disorders that currently have few effective options. Its primary drug candidate, Itolizumab, works by targeting a specific protein involved in harmful immune responses and is being tested across multiple conditions, including graft-versus-host disease, lupus, and ulcerative colitis. The company also has a second experimental therapy aimed at certain immune-driven cancers affecting the skin. Founded in 2017 and based in La Jolla, California, Equillium works alongside Biocon SA under a licensing agreement to advance its lead treatment.
